
FDA Advisory Panel Backs TRUQAP® (Capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
FDA Advisory Committee Backs TRUQAP® (capivasertib) for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee has delivered a largely favorable assessment of TRUQAP,…












